Argent Biopharma Ltd · ASX:RGT
Argent Biopharma — MGC Pharmaceuticals — Investor Presentation (January 2020)
25 slides from Argent Biopharma's investor presentation, January 2020
Slide 1: Leading The Way in Phytocannabinoid Derived Medicines
OVERVIEW MARKET APPENDIX Leading The Way in Phytocannabinoid Derived Medicines with a Seed to Medicine Strategy Company Presentation January 2020
Slide 2: Disclaimer
Disclaimer OVERVIEW The information contained in these slides and the accompanying verbal presentation (“Presentation”) is being The Presentation is confidential and must not be copied, reproduced, published, distributed, disclosed or used for supplied to you by MGC Pharmaceuticals Limited on behalf
Slide 3: Investment Highlights
Investment Highlights OVERVIEW MGC Pharma is a European based bio-pharma company supplying GMP Phytocannabinoid derived products to patients through the Company distribution channels, with products registered in UK, Ireland, Australia and Brazil EU-GMP certified manufacturing facility in Europe, m
Slide 4: Global Presence
Global Presence OVERVIEW Slovenia: Primary Research Base United Kingdom: • Botanical and Pharma research base • European Corporate Headquarters • Manufacturing centre with EU GMP • Planned LSE Standard dual listing Q1 2020 certification MARKET Malta: Primary Operation Base (Under Construction) APPEN
Slide 5: In Numbers
In Numbers OVERVIEW Established EU-GMP licence, operational in the cannabis for medicinal purposes space 2 Over 15 2 Years of Collective MARKET Operations Experience in Medical Developed IMP Facilities Cannabis Research Products Malta (under construction) & R&D team backed by extensive And pipeline
Slide 6: Global Market
Global Market OVERVIEW Estimated cannabis for Europe to be largest Nov 1st 2018 medicinal use value medical cannabis market. UK legalised prescription MARKET Total healthcare spend: of medical cannabis ~£51 billion in 2024 £2.1t products APPENDIX • MGC Pharma aims to secure a significant share in Po
Slide 7: Board of Directors
Board of Directors OVERVIEW Highly qualified team with over 15 years of relevant experience MARKET Roby Zomer Brett Mitchell Nativ Segev Dr. Stephen Parker Dr. Ross Walker Managing Director, CEO & Co. Executive Chairman Director, Head of Business Director & Chairman of Audit, Director & Founder Stra
Slide 8: Clinical Advisory Team
Clinical Advisory Team OVERVIEW Leading experts in the medical cannabis space with unparalleled expertise MARKET Dr Jonathan Grunfeld Professor Emeritus Professor David Dr Nadya Lisovoder Head of Oncology and Palliative Uri Kramer Head of Neubauer Head of Clinical Research (CRO) and product developm
Slide 9: Mission
Mission OVERVIEW Building a global bio-pharma company With: Standardised, Affordable Phytocannabinoid Derived Medicines 1. Engage in continuous research to maintain innovative position– Botanical and Pharmaceutical for the highest regulatory compliance medicines (EMA) MARKET 2. Advance commercialisa
Slide 10: Company Snapshot
Company Snapshot OVERVIEW MGC Pharma is at the forefront of Global Phytocannabinoid derived medicines EARLY PATIENT ACCESS SCHEME • MGC products are being accessed through Early Patient Access Schemes in Brazil, UK and QUALIFIED MANUFACTURING Australia MARKET • Strategic Alliance with Australia’s le
Slide 11: IP within Seed to Medicine strategy
IP within Seed to Medicine strategy OVERVIEW Creation and commercialisation of Phytocannabinoid derived products through a model utilising R&D capability with vertical IP development Global Research and Development From R&D to Commercialisation in New Centralised EU Hub • Multi-National base (AUS, E
Slide 12: MGC Clinical Research & Development
MGC Clinical Research & Development OVERVIEW 3 research areas based on medical experience and large data collections Lead by Ass. Prof Nitin Lead by Prof Uri Kramer Mantri (RMIT) Epilepsy Anti-Inflammatory Dementia Anti-Bacterial Cerebral Palsy MARKET Neurology Oncology Autoimmune APPENDIX Lead by D
Slide 13: Investigational Medicinal Products
Investigational Medicinal Products Phase I OVERVIEW Targeting specific medical conditions such as epilepsy and dementia Phase II Dementia & Alzheimer's Disease Epilepsy • Oral oil solution to • Oral spray utilising a treat seizures specific THC:CBD associated with drug ratio for relief of MARKET res
Slide 14: CannEpil
CannEpil® OVERVIEW CannEpil® is a Phytocannabinoid derived IMP used as a treatment for refractory epilepsy ® • Available to prescribe in Australia and UK CannEpil® is an oral oil solution of 20:1 as an Investigational Medicinal Product cannabidiol (CBD) and (-)- trans-Δ9- Neurological Disorders MARK
Slide 15: CogniCann
CogniCann™ OVERVIEW CogniCann™ is MGC Pharma’s second Phytocannabinoid derived IMP designed to improve dementia and Alzheimer’s disease patients quality of life ™ • Available to prescribe in Australia as an CogniCann™ is a oromucosal spray of Investigational Medicinal Product through cannabidiol (CB
Slide 16: Research and Development – Potential Products
Research and Development – Potential Products OVERVIEW • Developing medicines that leverage its proprietary medical cannabis formula through clinical trials in Europe and Australia • Enable future medical product sales across the EU, Australia and other geographies, following the legal and regulator
Slide 17: MGC Drug Delivery Development
MGC Drug Delivery Development OVERVIEW Smart nanostructured materials for drug delivery PCL Shell Nano-emulsion, Nano particles & Core-shell microcapsules MGC is currently conducting research on MARKET smart nanostructured materials to deliver drugs to the target sites with reduced dosage frequency
Slide 18: Strategic Partnership with RMIT
Strategic Partnership with RMIT OVERVIEW MGC Pharma and RMIT developing CannaHub, a digital research hub for the application of Phytocannabinoid derived medicines including the International Library of Cannabinoids (ILC) INTERNATIONAL LIBRARY OF CANNABINOIDS • ILC is the World’s first library of can
Slide 19: Other Strategic Partnerships: Cultivation & Production
Other Strategic Partnerships: Cultivation & Production OVERVIEW CULTIVATION PRODUCTION • Active engagement with multiple cultivation sites to meet • Production of high quality pharmaceutical products to be used increasing global demand as part of a prescribed medical treatment plan • Specialised con
Slide 20: Expansion Plan: Malta – a Centralised Hub
Expansion Plan: Malta – a Centralised Hub OVERVIEW Establishing a fully integrated medical cannabis “Seed to Medicine” operation in the EU Signed long-term lease on 6,000m2 site for full medical Medical Cannabis legalised in Malta – provides direct access cannabis facility providing direct access to
Slide 21: Key Wholesaler Partner
Key Wholesaler Partner OVERVIEW LENIS – A FULL-SERVICE PHARMACEUTICAL DISTRIBUTOR Lenis specializes in the distribution of unlicensed drugs and niche therapeutic areas (licensed in the source country but not in the destination country). This includes: • New drugs not yet approved in a country • Disc
Slide 22: Key Distribution Partners
Key Distribution Partners OVERVIEW Extensive network in place providing access to hospitals, pharmacies and research institutions around the world SOUTH AMERICA EUROPE AFRICA ASIA AUSTRALIA MARKET Distributor has a disruptive digital strategy to Distribution channels with a strong Health House speci
Slide 23: Projected Timelines
Projected Timelines OVERVIEW Working to achieve values over time as “Seed to Medicine” Bio-Pharma Company • 2,000 PRESCRIPTION Observational MILESTONE ACHIEVED IN Study AUSTRALIA , UK AND BRAZIL Commenced CogniCannTM InCann Clinical CannEpil® vs euGMP Clinical Programme Programme CBD Head-to- approv
Slide 24: Investment Case
Investment Case OVERVIEW Fully Integrated Model: Grow Develop Commercialise Built on Decades of Experience Technical team of globally recognised scientists and doctors Focussed Operations MARKET Core divisions: Research and Development Manufacturing and Distribution Strategically Located Operati
Slide 25: OVERVIEW APPENDIX
OVERVIEW https://mgcpharma.com.au/ MARKET @mgcpharamaceuticals @MGC_Pharma MGC Pharmaceuticals Ltd APPENDIX Financial PR: St Brides Partners (+44) 02072361177 info@stbridespartners.co.uk
MGC Pharmaceuticals — Investor Presentation (January 2020) on 6ix